



March 1, 2022

Web Announcement 2727

Silver State Scripts Board (SSSB) Makes Changes to Preferred Drug List (PDL) Effective March 1, 2022

The Silver State Scripts Board (SSSB) met on December 9, 2021, and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective March 1, 2022.

The complete PDL is posted on the [“Preferred Drug List”](#) webpage.

Drug Class/Program	Changes
Analgesics – Analgesic/Miscellaneous – Neuropathic Pain/Fibromyalgia Agents	Lidoderm® moved to preferred Pregabalin added as non-preferred Pregabalin ER added as non-preferred
Cardiovascular Agents – Antihypertensive Agents – Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)	Enalapril solution added to non-preferred
Cardiovascular Agents – Miscellaneous Heart Failure Agents (NEW)	Corlanor® added as preferred Entresto® added as preferred Verquvo® added as non-preferred
Electrolytic and Renal Agents – Potassium Removing Agents (NEW)	Lokelma® added as preferred Sodium Polystyrene Sulfonate added as preferred SPS® added as preferred Veltassa® added as non-preferred
Genitourinary Agents – Bladder Antispasmodics	Detrol® moved to preferred Detrol LA® moved to preferred Gemtesa® added as non-preferred
Hormones and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics Agents	Trulicity® moved to preferred
Hormones and Hormone Modifiers – Anti-Hypoglycemic Agents	Baqsimi® moved to preferred Glucagen® added as preferred Glucagon emergency kit moved to non-preferred Zegalogue® added as preferred
Neurological Agents – Anti-Migraine Agents – Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists	Qulipta® added as preferred
Neurological Agents – Movement Disorders (NEW)	Austedo® added as preferred Ingrezza® added as preferred Tetrabenazine added as preferred Xenazine® added as non-preferred

Drug Class/Program	Changes
Ophthalmic Agents – Ophthalmic for Dry Eye Disease	Eysuvis® added as non-preferred Xiidra® moved to preferred
Psychotropic Agents – Antipsychotics – Atypical Antipsychotics - Long-Acting Injectable	Invega® Hafyera added as preferred
Psychotropic Agents – Antipsychotics – Atypical Antipsychotics - Oral/Topical	Geodon® moved to preferred Lybalvi® added as non-preferred Ziprasidone moved to non-preferred
Toxicology Agents – Antidotes – Opiate Antagonists	Kloxxado® added as preferred